Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of GLPG1837 Tablet vs Suspension
NCT02562859Phase 1Completed
- Sponsor
- Galapagos NV
- Start
- Sep 2015
- Primary completion
- Oct 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of GLPG1837 in cystic fibrosis (CF) (3 arms), sponsored by Galapagos NV. Primary endpoints: Maximum Observed Plasma Concentration, Plasma Concentration at 24 Hours and 4 more. Started Sep 2015; status: completed.
02
Drugs
GLPG1837
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT02562859.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02562859.